Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643495 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT05643495 is a Phase 2 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 14 participants.
The verdict
NCT05643495, a Phase 2 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study evaluates the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.
Interventions
- DRUG VX-864
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2024-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05643495
The ClinicalTrials.gov registry entry for NCT05643495 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-864 is the first listed.
NCT05643495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05643495 about?
NCT05643495 is a clinical study titled "A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype". The purpose of this study evaluates the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.
What is the current status of trial NCT05643495?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2023-02-23. Estimated completion is 2024-08-19.
What interventions are being tested in trial NCT05643495?
The interventions under investigation include: VX-864 (DRUG).
Who is sponsoring clinical trial NCT05643495?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.